Clinical predictors of thiopurine-related adverse events in Crohn's disease

Table 4 Stratified multivariate analysis

Adjusted variables		Adjusted OR (95%CI)
	All cohort (n = 351)	Female (n = 185)	Male (n = 166)
Age at Thiopurine prescription > 40 (sex-by-age interaction, P = 0.04)	2.4 (1.4-4.2)	2.8 (1.4-5.6)	0.9 (0.4-2.1)
Female vs male (referent)	1.2 (0.7-2.0)	NA	NA
Smoking history (current/past)	1.5 (0.9-2.5)	1.5 (0.8-3.1)	1.6 (0.8-3.6)
Pre-thiopurine intestinal resection vs no resection (referent)	0.86 (0.43-1.71)	0.7 (0.3-1.8)	1.0 (0.4-2.8)
L1 vs L2 (referent)	1.4 (0.6-3.2)	1.2 (0.4-3.6)	3.1 (0.9-10.4)
L3 vs L2 (referent)	1.5 (0.7-3.0)	1.1 (0.4-2.7)	2.1 (0.7-6.3)
B2 vs B1 (referent)	1 (0.5-2.2)	1.0 (0.3-2.8)	0.7 (0.2-2.4)
B3 vs B1 (referent)	1.1 (0.5-2.5)	1.0 (0.3-2.8)	0.8 (0.3-2.5)
Pre-thiopurine perianal disease vs no perianal disease (referent)	0.7 (0.4-1.3)	1.1 (0.5-2.7)	0.7 (0.3-1.8)
5-ASA at time of thiopurine vs past or never (referent)	0.8 (0.4-1.5)	0.7 (0.3-1.8)	1.0 (0.4-2.4)
Corticosteroid at diagnosis vs no exposure at diagnosis (referent)	0.9 (0.5-1.6)	0.7 (0.3-1.5)	0.9 (0.4-2.2)
L4 vs L2 (referent)	1.8 (0.7-4.3)	3.4 (0.9-12.2)	0.9 (0.3-3.1)

Predictors of thiopurine discontinuation in all cohort and as determined by this stratified multivariate analysis by sex. Demographic data suggests a higher incidence of adverse events in female patients over the age of 40 years. An age-by-gender interaction is seen as described in this multivariate analysis of thiopurine-exposed patients in female subjects over the age of 40 years. ASA: Aminosalicylic acid; NA: Not available.